3M Reports Fourth-Quarter and Full-Year 2025 Results; Initiates Full-Year 2026 Financial Guidance
Q4 GAAP sales of $6.1 billion, up 2.1%; operating margin of 13.0%, down 510 bps; EPS of $1.07, down 20%,...
Year: 2026
3M Reports Fourth-Quarter and Full-Year 2025 Results; Initiates Full-Year 2026 Financial Guidance
Q4 GAAP sales of $6.1 billion, up 2.1%; operating margin of 13.0%, down 510 bps; EPS of $1.07, down 20%,...
3M Reports Fourth-Quarter and Full-Year 2025 Results; Initiates Full-Year 2026 Financial Guidance
Q4 GAAP sales of $6.1 billion, up 2.1%; operating margin of 13.0%, down 510 bps; EPS of $1.07, down 20%,...
Patient Engagement Solutions Market to Grow at a Robust CAGR of 21.25%, Crossing USD 229.5 Billion by 2035 | Vantage Market Research
NEW YORK , Jan. 20, 2026 /PRNewswire/ -- The Global Patient Engagement Solutions Market is undergoing a profound transformation as healthcare systems worldwide...
Patient Engagement Solutions Market to Grow at a Robust CAGR of 21.25%, Crossing USD 229.5 Billion by 2035 | Vantage Market Research
NEW YORK , Jan. 20, 2026 /PRNewswire/ -- The Global Patient Engagement Solutions Market is undergoing a profound transformation as healthcare systems worldwide...
Patient Engagement Solutions Market to Grow at a Robust CAGR of 21.25%, Crossing USD 229.5 Billion by 2035 | Vantage Market Research
NEW YORK , Jan. 20, 2026 /PRNewswire/ -- The Global Patient Engagement Solutions Market is undergoing a profound transformation as healthcare systems worldwide...
Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis
The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...
Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis
The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...
Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis
The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...
Beyond Benign’s Green Chemistry Commitment Earns 2025 RSC Horizon Prize for Education for Advancing Green Chemistry in Higher Education
NORTHAMPTON, MA / ACCESS Newswire / January 20, 2026 / Beyond Benign's Green Chemistry Commitment (GCC) has been awarded the...
Beyond Benign’s Green Chemistry Commitment Earns 2025 RSC Horizon Prize for Education for Advancing Green Chemistry in Higher Education
NORTHAMPTON, MA / ACCESS Newswire / January 20, 2026 / Beyond Benign's Green Chemistry Commitment (GCC) has been awarded the...
Beyond Benign’s Green Chemistry Commitment Earns 2025 RSC Horizon Prize for Education for Advancing Green Chemistry in Higher Education
NORTHAMPTON, MA / ACCESS Newswire / January 20, 2026 / Beyond Benign's Green Chemistry Commitment (GCC) has been awarded the...
Saint Therese of Oxbow Lake Earns 2025 Zellner Group Client of the Year Award
Brooklyn Park, MN senior care community recognized for exceptional partnership, leadership, and commitment to resident-centered care ST LOUIS PARK, MN...
Saint Therese of Oxbow Lake Earns 2025 Zellner Group Client of the Year Award
Brooklyn Park, MN senior care community recognized for exceptional partnership, leadership, and commitment to resident-centered care ST LOUIS PARK, MN...
Saint Therese of Oxbow Lake Earns 2025 Zellner Group Client of the Year Award
Brooklyn Park, MN senior care community recognized for exceptional partnership, leadership, and commitment to resident-centered care ST LOUIS PARK, MN...
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable...
Adia Nutrition Inc. Receives Notification from SEC: Form 10 to Become Effective on February 3, 2026
Winter Park, Florida--(Newsfile Corp. - January 20, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and...
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu...
Black Book Research Releases “New Zealand Acute Care EMR & Digital Health 2026” Companion Report
New analysis details the national platforms, standards, and vendor landscape shaping EMR consolidation, interoperability, medicines safety, and cyber resilience across...
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat...